Supercharge Your Innovation With Domain-Expert AI Agents!

Use of oxycaine in preparation of medicine and pharmaceutical composition

A technology for the preparation of oxycaine and drugs, which is applied in the field of biomedicine, can solve the problems that oxycaine needs to be further developed, and achieve the effects of low toxicity, high bioavailability, and clear metabolic pathways

Inactive Publication Date: 2019-07-05
WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, the use of oxycaine has yet to be further developed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of oxycaine in preparation of medicine and pharmaceutical composition
  • Use of oxycaine in preparation of medicine and pharmaceutical composition
  • Use of oxycaine in preparation of medicine and pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] The evaluation of embodiment 1 oxycaine anti-HBV activity

[0048] 1. Experimental materials

[0049] 1.1 Cells and Drugs

[0050] HepAD38 cell line: Human liver cancer stable transfection cell line, the HBV genome is integrated in its chromosome, which can support HBV DNA synthesis and protein expression, and can produce infectious virus particles. Viral replication in this cell line is controlled by the tetracycline-regulated CMV promoter.

[0051] Oxycaine was purchased from Sigma, and lamivudine (3TC) was a gift from NIH.

[0052] 1.2 Reagents

[0053] DMEM / F12 medium and fetal bovine serum (FBS) were purchased from GIBCO; HBV surface antigen (S antigen) and e antigen detection kits were purchased from Shanghai Kehua Biotechnology Co., Ltd.; Reagents were purchased from Invitrogen; iTaqUniversal SYBR Green supermix reagent was purchased from Bio-rad; DIG High Prime DNA Labeling and Detection Starter Kit II was purchased from Roche.

[0054] 2. Experimental met...

Embodiment 2

[0076] Example 2 Oxethazaine directly acts on HBV nucleocapsid assembly to exert antiviral effect

[0077] 1. Experimental materials

[0078] 1.1 Cells, plasmids and drugs

[0079] HepAD38 cell line: Human liver cancer stable transfection cell line, the HBV genome is integrated in its chromosome, which can support HBV DNA synthesis, protein expression, and produce infectious virus particles. Viral replication in this cell line is controlled by the tetracycline-regulated CMV promoter.

[0080] Huh7 is a human liver cancer cell, donated by Chen Xinwen, a researcher at Wuhan Institute of Virology.

[0081] pFlag-GAPDH is a plasmid expressing the GAPDH protein fused with the Flag tag under the control of the CMV promoter constructed in our laboratory;

[0082] Oxycaine was purchased from Sigma, and lamivudine (3TC) was a gift from NIH.

[0083] 1.2 Reagents

[0084] MEM and DMEM / F12 medium and fetal bovine serum (FBS) were purchased from GIBCO; Reagents and transfection rea...

Embodiment 3

[0126] Embodiment 3 Oxethazaine (Oxethazaine) is to the antiviral effect of nucleoside analog drug-resistant HBV mutant strain

[0127] 1. Experimental materials

[0128] 1.1 Cells, plasmids and drugs

[0129] Huh7 is a human liver cancer cell;

[0130] Plasmid REZ31-9-1 (59#) contains 1.1 times the wild-type HBV genome sequence; adefovir (ADV) resistant mutant strain expression plasmid REZ36-10-1 (61#), which contains 1.1 times the N236T mutation HBV genome sequence; lamivudine (3TC) and entecavir (ETV) double-resistant mutant strain expression plasmid REZ7-8-4 (70#), which contains 1.1 times the HBV genome sequence of L180M+M204V+S202G triple mutation. The above plasmids were donated by Chen Xinwen, researcher of Wuhan Institute of Virology.

[0131] Oxycaine was purchased from Sigma, lamivudine (3TC) was a gift from NIH; adefovir (ADV) and entecavir (ETV) were purchased from Dalian Meilun Biotechnology Co., Ltd.

[0132] 1.2 Reagents

[0133] DMEM medium and fetal bovi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of oxethazaine or pharmaceutically acceptable salt thereof in preparing medicines and a pharmaceutical composition for preventing or treating hepatitis B virus infection. The medicines or the pharmaceutical composition, which can effectively inhibit assembling of hepatitis B virus particles, can be used for effectively preventing and treating the hepatitis B virus infection.

Description

technical field [0001] The present invention relates to the field of biomedicine. Specifically, the present invention relates to the use and pharmaceutical composition of oxycaine in the preparation of medicines. More specifically, the present invention relates to the use of oxycaine or a pharmaceutically acceptable salt thereof in the preparation of medicines. and a pharmaceutical composition for treating or preventing hepatitis B virus infection. Background technique [0002] Hepatitis B virus (HBV) infection is the most common chronic viral infection in the world. HBV is mainly transmitted through blood transmission, sexual transmission, mother-to-child transmission and other ways. Hepatitis B virus infection is the world's top health problem, causing 768,000 deaths per year worldwide, and is the tenth leading cause of death in the world. [0003] At present, there are only two kinds of interferons used in clinical treatment of hepatitis B virus infection, which are div...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/165A61P31/20
Inventor 陈绪林张林
Owner WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com